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Introduction to Comment 
Biomedical research is now a field not only opens to the 
gathering of medical data on diagnostic tests, epidemic research 
and disease prevention and cure. The purpose of biomedical 
research is now properly changed to the application modern 
methods of scientific sophistication whereby operations research, 
statistical analytics and analysis and data management often 
referred to as “Data Science” and for marketing purposes “Big 
Data.”Research methods are now everywhere one sees from the 
production of most automotive parts to the check-out lines at most 
supermarkets and the design of seating arrangement to maximize 
cash inflow on aircraft. Not all satisfy all users of technological 
improvement but they are everywhere to satisfy the desires of the 
decision makers whose goals vary but often provide satisfaction to 
them. In the medical sciences, we observe trends in the direction 
of great changes in patient care and quicker methods for decision 
purposes. We often refer to this as automation but it is the 
advances in computer technologies that drive this mechanization 
of seemingly simple but technological advanced tasks to streamline 
patient care methodologies. The growth of these technologies in 
the future will speed up by breakthroughs in artificial intelligence 
which will continue the mechanization of tasks improve the 
quality of disease control, production of new pharmaceuticals, 
intensive care improvement, disease and epidemic prevention and 
water pollution and treatments after horrific storms which bring 
problems to keeping water pure, available and easy to transport to 
areas having great difficulties handling the aftermath of destructive 
environment conditions. Artificial Intelligence (AI) includes the 
leadership in Forensic Science Laboratories; Forensic Laboratory 
Key Business Metrics and Cost–Benefit Analyses; Laboratory 
Excellence and Ethics: An Essential Association; Laboratory 
Excellence and Ethics: An Essential Association; ISO Accreditation 
Implementation: A Framework to Implement a Quality and Writing 
Policies and Procedures.
A Simple Example of Pharmaceutical Testing
New pharmaceutical testing is a subject matter where a new 
cure for a disease is compared with two sample independently 
drawn where one group is given the experimental drug and second 
sample is given a placebo, a substance containing no medicinal 
value. Scientific testing requires the researcher to determine if there 
is a statistically scientific difference in the result of the experiment 
and furthermore the experiment drug produces better result and 
often how much better. Medical controls are often implement in 
order that the two independently drawn samples differ only with 
respect to whether the sample differs only by which pill is taken by 
the patient. The problem is whether the sample are large enough 
to draw scientific conclusions or the groups are dissimilar in 
other ways that can affect the final curative results. Furthermore, 
more scientific and sophisticated analyses could be employed that 
explain real differences when they occur. Multivariate statistical 
methods could be employed to examine the results which would 
lead analysts to quicker and better conclusion. In addition, data 
science and AI will produce the same results without human 
interference which enable much faster certainty in the results and 
bring new drugs to market at an exponentially faster pace.
Conclusion
The previous example and discussion will lead to great benefits 
for society. The above commentary leads to medical researchers 
rethinking their methodology, goal and purpose. The blending of 
intelligent (AI) software and comprehensive data analytics will 
eventually move health care analysts from the task of interpreting 
results to have protocols produced for them. Intelligent software 
will blend seamlessly with a decision maker’s operations insights 
and produce a unique domain expertise to create better analytical 
conclusions in the world we live in and certainly after horrendous 
climatic events.
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